Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Qi Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5287-6050; OpenAlex author ID A5100341303. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2022: 1 paper · 2023: 5 papers · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Targeting MTPN sensitizes pancreatic cancer of wild-type BRCA1/2 to Cisplatin-based chemotherapy. Co-author DOI 10.1038/s41417-025-00925-5↗
  2. Pan-Cancer Analysis Reveals SOX2 as a Promising Prognostic and Immunotherapeutic Biomarker Across Various Cancer Types, Including Pancreatic Cancer. Co-author DOI 10.7150/jca.88397↗
  3. LncRNA FAM83A-AS1 promotes epithelial-mesenchymal transition of pancreatic cancer cells via Hippo pathway. Co-author DOI 10.1080/15384101.2023.2216507↗
  4. CTSK and PLAU as Prognostic Biomarker and Related to Immune Infiltration in Pancreatic Cancer: Evidence from Bioinformatics Analysis and qPCR. Co-author DOI 10.1155/2023/3914687↗
  5. NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation. Co-author DOI 10.3389/fimmu.2023.1097403↗
  6. Unveiling the role of regulatory T cells in the tumor microenvironment of pancreatic cancer through single-cell transcriptomics and in vitro experiments. Co-author DOI 10.3389/fimmu.2023.1242909↗
  7. Single-cell RNA sequencing identifies a novel proliferation cell type affecting clinical outcome of pancreatic ductal adenocarcinoma. First author DOI 10.3389/fonc.2023.1236435↗
  8. The Role of Adipokines in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.926230↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuntao Ding · 4 shared papers, 2022–2024 · strength 0.84
  2. Huizhi Wang · 3 shared papers, 2022–2023 · strength 0.61
  3. Min Xu · 2 shared papers, 2023 · strength 0.41
  4. Lifu Wang · 1 shared paper, 2025 · strength 0.26
  5. Zhuoxin Wang · 1 shared paper, 2025 · strength 0.26
  6. Tingting Gong · 1 shared paper, 2025 · strength 0.26
  7. Yixun Jin · 1 shared paper, 2025 · strength 0.26
  8. Huizhi Wang · 1 shared paper, 2024 · strength 0.23
  9. Min Xu · 1 shared paper, 2024 · strength 0.23
  10. Aihua Gong · 1 shared paper, 2023 · strength 0.20
  11. Min Xu · 1 shared paper, 2022 · strength 0.20
  12. Qiang Li · 1 shared paper, 2023 · strength 0.19
  13. Wei Xu · 1 shared paper, 2023 · strength 0.19
  14. Chunfang Xu · 1 shared paper, 2023 · strength 0.19
  15. Wenjia Zhang · 1 shared paper, 2023 · strength 0.19
  16. Min Xu · 1 shared paper, 2023 · strength 0.18
  17. Xu‐Feng Huang · 1 shared paper, 2023 · strength 0.18
  18. Shujing Zhou · 1 shared paper, 2023 · strength 0.18
  19. Lingling Zeng · 1 shared paper, 2023 · strength 0.17
  20. Bicheng Ye · 1 shared paper, 2023 · strength 0.17
  21. Jingen Xie · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.